Kim Nan Hee, Seo Ji A, Cho Hyunjoo, Seo Ji Hye, Yu Ji Hee, Yoo Hye Jin, Kim Sin Gon, Choi Kyung Mook, Baik Sei Hyun, Choi Dong Seop, Shin Chol, Cho Nam Han
From the Division of Endocrinology (NHK, JAS, HC, JHS, JHY, HJY, SGK, KMC, SHB, DSC); Division of Pulmonary and Critical Care Medicine (CS), Department of Internal Medicine, Korea University College of Medicine, Seoul; and Department of Preventive Medicine (NHC), Ajou University School of Medicine, Suwon, Korea.
Medicine (Baltimore). 2016 Apr;95(15):e3384. doi: 10.1097/MD.0000000000003384.
The reported effects of a metabolically healthy obese (MHO) phenotype on diabetes and cardiovascular disease (CVD) risk are contradictory. Within the context of a population-based cohort study, we aimed to investigate the long-term risk of an MHO status for the development of diabetes and CVD, and whether consistency of this phenotype or age affected cardiometabolic outcomes. We recruited 7588 subjects without diabetes or CVD, aged 40 to 69 years at baseline examination, from the Korean Genome and Epidemiology Study, and followed-up these subjects for 10 years biennially. Participants were divided into 4 groups based on the body mass index and the presence of metabolic syndrome: metabolically healthy normal weight (MHNW), MHO, metabolically unhealthy normal weight (MUNW), and metabolically unhealthy obese (MUO). We defined persistent phenotypes if subjects maintained the same phenotype at every visit from baseline to their last visit. Incident diabetes and CVD morbidity or mortality were identified during 10 years of follow-up. Compared to MHNW controls, MUNW and MUO groups had increased risk for development of diabetes (hazard ratio [HR] 3.0 [95% CI: 2.5-3.6], and 4.0 [3.4-4.7], respectively) and CVD (HR 1.6 [1.3-2.0], and 1.9 [1.5-2.4], respectively). However, the MHO group showed only a marginal increase in risk for diabetes and CVD (HR 1.2 [0.99-1.6], 1.4 [0.99-1.8], respectively). The impact of MHO on the development of diabetes was more prominent in younger individuals (HR 1.9 [1.2-3.1] vs 1.1 [0.8-1.4], <45 years vs ≥45 years at baseline). Only 15.8% of MHO subjects maintained the MHO phenotype at every visit from baseline to the 5th biennial examination (persistent MHO). In subjects with persistent MHO, the risk for diabetes and CVD was significantly higher than those with persistent MHNW (1.9 [1.2-3.1], 2.1 [1.2-3.7], respectively). MHO phenotype, even if maintained for a long time, was associated with a significantly higher risk for the development of diabetes and CVD in Korean subjects.
代谢健康型肥胖(MHO)表型对糖尿病和心血管疾病(CVD)风险的影响报道不一。在一项基于人群的队列研究中,我们旨在调查MHO状态对糖尿病和CVD发生的长期风险,以及该表型的一致性或年龄是否会影响心脏代谢结局。我们从韩国基因组与流行病学研究中招募了7588名无糖尿病或CVD的受试者,他们在基线检查时年龄为40至69岁,并每两年对这些受试者进行一次为期10年的随访。根据体重指数和代谢综合征的存在情况,将参与者分为4组:代谢健康正常体重(MHNW)、MHO、代谢不健康正常体重(MUNW)和代谢不健康肥胖(MUO)。如果受试者从基线到最后一次就诊每次就诊时都保持相同的表型,我们则定义为持续表型。在10年的随访期间确定了新发糖尿病和CVD的发病率或死亡率。与MHNW对照组相比,MUNW和MUO组患糖尿病的风险增加(风险比[HR]分别为3.0[95%CI:2.5 - 3.6]和4.0[3.4 - 4.7])以及患CVD的风险增加(HR分别为1.6[1.3 - 2.0]和1.9[1.5 - 2.4])。然而,MHO组患糖尿病和CVD的风险仅略有增加(HR分别为1.2[0.99 - 1.6]和1.4[0.99 - 1.8])。MHO对糖尿病发生的影响在较年轻个体中更为突出(HR为1.9[1.2 - 3.1],而基线时年龄<45岁与≥45岁相比为1.1[0.8 - 1.4])。从基线到第5次两年期检查,只有15.8%的MHO受试者每次就诊时都保持MHO表型(持续MHO)。在持续MHO的受试者中,患糖尿病和CVD的风险显著高于持续MHNW的受试者(分别为1.9[1.2 - 3.1]和2.1[1.2 - 3.7])。在韩国受试者中,即使长期保持MHO表型,其患糖尿病和CVD的风险也显著更高。